MedTrace Logo

α-N-acetylgalactosaminidase in Methamphetamine Psychosis

NCT07434401 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 93

Last updated 2026-02-25

No results posted yet for this study

Summary

This cross-sectional observational cohort study examined serum α-N-acetylgalactosaminidase levels in methamphetamine use disorder (MUD), methamphetamine-induced psychotic disorder (MP), and healthy control (HC) groups. The study aimed to determine whether decreased α-N-acetylgalactosaminidase levels are associated with psychotic symptoms in methamphetamine users.

Conditions

  • Methamphetamine Use Disorder
  • Methamphetamine-induced Psychosis

Sponsors & Collaborators

  • Elazığ Mental Health and Diseases Hospital

    lead OTHER_GOV

Principal Investigators

  • Mehmet Hamdi ÖRÜM, MD, Associate Professor · Elazığ Mental Health and Diseases Hospital

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-01
Primary Completion
2025-08-31
Completion
2025-08-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07434401 on ClinicalTrials.gov